The Evolving Role of Platinums and Biologics
in the Treatment of Lung Cancer

Date of Release: March, 2004
Expiration Date: March, 2005

Print Page

Program Description

Recent phase III cooperative group trials have re-established the role of platinum-based therapy in advanced NSCLC (S9509, E1594, C9730). Controversy still remains with respect to the use of non-platinum regimens, particularly for the treatment of elderly and PS 2 patients. New trials will also determine the role of platinum for resectable stage I-III NSCLC, in combination with new agents in SCLC, and how to optimize delivery of platinum-based chemotherapy in all stages of lung cancer (eg., new weekly regimens). Also, the role of newly targeted molecular agents is still evolving, with respect to combining these new agents with chemotherapy. This program will provide a foundation for evaluating future clinical investigations in lung cancer.

Program Objectives

Upon completion of this educational activity, participants should be able to:

Section 1

1. Discuss the rationale to explore new treatment options in all stages of lung cancer.
2. Describe the evolving role of novel therapies in combination with platinum therapy.
3. Identify the advantages and disadvantages with the use of platinum therapy.
4. Identify ongoing and future clinical investigations for the treatment of early stage NSCLC.

Section 2

1. Discuss the rationale to explore new treatment options in advanced lung cancer.
2. Describe the evolving role of novel therapies in combination with platinum therapy.
3. Identify the advantages and disadvantages with the use of platinum therapy.
4. Identify ongoing and future clinical investigations for the treatment of advanced lung cancer.

Section 3

1. Discuss the rationale to explore new treatment options in advanced lung cancer.
2. Describe the evolving role of novel therapies in combination with platinum therapy.
3. Identify the advantages and disadvantages with the use of platinum therapy in elderly, PS2 patients.
4. Identify ongoing and future clinical investigations for stage III lung cancer.

Section 4

1. Discuss the rationale to explore new treatment options in SCLC.
2. Describe the evolving role of novel therapies in combination with platinum therapy.
3. Identify ongoing and future clinical investigations for the treatment of lung cancer.

Print Page

Close Window